Current disease-modifying treatment of multiple sclerosis

Mount Sinai Journal of Medicine

Volumn 78, Issue 2, 2011, Pages 161-175

  Derwenskus, Joy ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

beta interferon; disease modifying therapy; fingolimod; glatiramer acetate; mitoxantrone; multiple sclerosis; natalizumab

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GILENYA; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ALOPECIA; AMENORRHEA; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ERYTHEMA; HUMAN; INJECTION SITE INFLAMMATION; LYMPHOCYTOPENIA; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; NAUSEA; PAIN; PATIENT PREFERENCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECOMMENDED DRUG DOSE; RELAPSE; SIDE EFFECT; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MITOXANTRONE; MULTIPLE SCLEROSIS; PATIENT SELECTION; PEPTIDES; PROPYLENE GLYCOLS; RECURRENCE; SPHINGOSINE;

EID: 79953017502     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20239     Document Type: Article

References (48)

1. Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998 51 682-689. (Pubitemid 28449243)
2. Zhang X, Markovic-Plese S., Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis. Clin Neurol Neurosurg 2010 2010 641-645.
3. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 43 655-661.
4. Paty DW, Li DKB., Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 43 662-667. (Pubitemid 23121952)
5. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995 45 1277-1285.
6. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996 39 285-294. (Pubitemid 26100751)
7. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998 352 1498-1504.
8. Li DKB, Paty DW., Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999 46 197-206. (Pubitemid 29382876)
9. The PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon β-1a in relapsing MS. Neurology 2001 56 1628-1636.
10. Walther EU, Hohfeld R., Multiple sclerosis side effects of interferon beta therapy and their management. Neurology 1999 53 1622-1627. (Pubitemid 29530329)
11. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003 362 1184-1191. (Pubitemid 37255344)
12. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN). Lancet 2002 359 1453-1460. (Pubitemid 34457761)
13. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002 59 1496-1506. (Pubitemid 35387053)
14. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995 45 1268-1276.
15. Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (copaxone) treatment in relapsing-remitting MS quantitative MR assessment. Neurology 2000 54 813-817. (Pubitemid 30111334)
16. Comi G, Filippi M, Wolinsky JS, et al. European/ Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001 49 290-297. (Pubitemid 32202781)
17. Wolinsky JS, Comi G, Filippia M, et al. Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology 2002 59 1284-1286. (Pubitemid 35192412)
18. Fox EJ., Mechanism of action of mitoxantrone. Neurology 2004 63 Suppl 6 S15-S18. (Pubitemid 40019273)
19. Hartung HP, Consette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002 360 2018-2025. (Pubitemid 36026580)
20. Krapf H, Morrissey SP, Zender O, et al. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2005 65 690-695. (Pubitemid 41285846)
21. Edan G, Brochet B, Clanet M, et al. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients: a 4 year mean follow-up study. Neurology 2004 62 suppl 5 A493.
22. Avasarala JR, Cross AH, Clifford DB, et al. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 2003 9 59-62. (Pubitemid 36253698)
23. Paul F, Dorr J, Wurfel J, et al. Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2007 78 198-200. (Pubitemid 46220225)
24. Marriott JJ, Miyasaki JM, Gronseth G, et al. Evidence report: the efficacy and safety of mitoxantrone (novantrone) in the treatment of multiple sclerosis. Neurology 2010 74 1463-1470.
25. Bosca I, Pascual AM, Casanova B, et al. Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone. Neurology 2008 71 457-458.
26. Ransohoff RM., Natalizumab for multiple sclerosis. N Engl J Med 2007 356 2622-2629. (Pubitemid 46961007)
27. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 354 899-901.
28. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006 354 911-923.
29. Langer-Gould A, Atlas SW, Green AJ., Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005 353 375-381. (Pubitemid 41132342)
30. Kleinschmidt-DeMasters BK, Tyler KL., Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005 353 369-374. (Pubitemid 41132341)
31. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoenchephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005 353 362-368. (Pubitemid 41132340)
32. Yousry TA, Habil M, Major EO, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006 354 924-933.
33. Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009 361 1081-1087.
34. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010 68 295-303.
35. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007 69 1391-1403. (Pubitemid 47511460)
36. Horga A, Castillo J, Montalban X., Fingolimod for relapsing multiple sclerosis: an update. Expert Opin Pharmacother 2010 11 1183-1196.
37. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010 362 387-401.
38. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010 362 402-415.
39. Jacobs DL, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a demyelinating event in multiple sclerosis. N Engl J Med 2000 343 898-904.
40. Comi G, Fllippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001 357 1576-1582. (Pubitemid 32488815)
41. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006 67 1242-1249. (Pubitemid 44563835)
42. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009 8 987-997.
43. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomized, double-blind, placebo-controlled trial. Lancet 2009 374 1503-1511.
44. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled study. Ann Neurol 2007 61 14-24. (Pubitemid 46214240)
45. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998 352 1491-1497.
46. Panitch H, Miller A, Weinshenker B, et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004 63 1788-1795. (Pubitemid 39532370)
47. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (The REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] Study): a multicentre, randomised, parallel, open label trial. Lancet Neurol 2008 7 903-914.
48. O'Connor P, Filippi M, Arnason B, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009 8 889-897.